Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
News|Articles|October 1, 2024
Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma
Author(s)Russ Conroy
Fact checked by: Ariana Pelosci
UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.
Advertisement
Advertisement
Weekly on-line MR-Linac (MRL) adaptive radiotherapy plus concurrent temozolomide (Temodar) appeared safe and feasible while significantly reducing the clinical target volume (CTV) margins and normal brain tissue exposure among patients with high-grade glioma, according to findings from the phase 2 UNITED trial (NCT04726397) presented at the
Related to this article
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
The FDA has approved a FET-PET imaging agent, to help characterize recurrent or progressive glioma from treatment-related changes.
Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.
Josef Vymazal, MD, discussed a randomized study showing delayed double-dose gadopiclenol significantly improved detection of small brain metastases compared with standard imaging.
Advertisement
Advertisement